Novartis’ Cosentyx Shows Very Little Radiographic Progression in Ankylosing Spondylitis Patients
Novartis recently reported that long-term radiographic data from a clinical trial showed that treatment of ankylosing spondylitis (AS) with Cosentyx (secukinumab) resulted in no disease progression in a vast majority of the patients analyzed. The multi-center, Phase 3 MEASURE I study (NCT01358175) showed that almost 80 percent of AS…